生化检验项目在肝硬化患者诊断中的临床价值分析  

Clinical Value Analysis of Biochemical Test Items in the Diagnosis of Patients With Liver Cirrhosis

作　　者：姚映生 许锡荣[1] YAO Yingsheng;XU Xirong(Department of Laboratory Medicine,Shantou Central Hospital,Shantou Guangdong 515041,China)

机构地区：[1]汕头市中心医院检验科,广东汕头515041

出　　处：《中国卫生标准管理》2025年第4期124-127,共4页China Health Standard Management

基　　金：2023年上半年汕头市医疗卫生科技计划(自筹经费类)项目(汕府科[2023]68号)。

摘　　要：目的分析在肝硬化诊断中,生化检验项目对疾病诊断的作用。方法抽取2022年1月—2023年12月就诊汕头市中心医院的肝硬化患者82例设为分析组,另选取同时期的健康体检者50名设为参比组。比较2组肝脏生化检验指标:胆碱酯酶(cholinesterase,CHE)、γ-谷氨酰转肽酶(γ-glutamyl transferase,γ-GT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)、丙氨酸氨基转移酶(alanine aminotransferase,ALT)、白蛋白(albumin,ALB)、碱性磷酸酶(alkaline phosphatase,ALP)、直接胆红素(direct bilirubin,DBiL)、总胆红素(total bilirubin,TBiL)、总胆汁酸(total bile acid,TBA)数据差异。结果分析组CHE为(2125.52±738.52)U/L、γ-GT为(19.11±5.45)U/L,低于参比组的(7135.52±2285.52)U/L、(127.52±35.19)U/L,差异均有统计学意义(P<0.001)。分析组AST为(94.74±11.60)U/L、ALT为(55.79±9.70)U/L,高于参比组的(13.93±2.52)U/L、(13.51±2.36)U/L,差异均有统计学意义(P<0.001)。分析组ALB水平为(22.38±2.73)g/L,低于参比组的(42.14±2.77)g/L,差异有统计学意义(P<0.001)。分析组ALP为(172.05±9.44)U/L、DBi L为(53.67±4.02)μmol/L、TBi L为(88.78±11.75)μmol/L、TBA为(66.74±4.27)μmol/L,高于参比组的(71.57±5.85)U/L、(3.60±0.26)μmol/L(、11.24±3.03)μmol/L(、7.01±0.04)μmol/L,差异均有统计学意义(P<0.001)。结论肝硬化患者与健康体检人群对肝脏相关生化检验项目指标差异显著,可根据数据水平对患者疾病诊断,同时为后期临床治疗提供充足数据,利于提升诊断准确率。Objective To analyze the role of biochemical test items in the diagnosis of liver cirrhosis.Methods A total of 82 patients with liver cirrhosis in Shantou Central Hospital from January 2022 to December 2023 were selected as the analysis group,and 50 healthy people in the same period were selected as the intake reference group.The liver biochemical test indexes(cholinesterase(CHE),γ-glutamyl transferase(γ-GT)),aspartate aminotransferase(AST),alanine aminotransferase(ALT),albumin(ALB),alkaline phosphatase(ALP),direct bilirubin(DBiL),total bilirubin(TBiL),total bile acid(TBA)were compared between the two groups.Results The CHE of the analysis group was(2125.52±738.52)U/L,and theγ-GT was(19.11±5.45)U/L,which was lower than those of the reference group[(7135.52±2285.52)U/L and(127.52±35.19)U/L],and the differences were statistically significant(P<0.001).The AST and ALT values of the analysis group were(94.74±11.60)U/L and(55.79±9.70)U/L,respectively,which were higher than those of the reference group[(13.93±2.52)U/L and(13.51±2.36)U/L],respectively,and the differences were statistically significant(P<0.001).The ALB level in the analysis group was(22.38±2.73)g/L,which was lower than that in the reference group[(42.14±2.77)g/L],and the difference was statistically significant(P<0.001).The ALP of the analysis group was(172.05±9.44)U/L,DBiL was(53.67±4.02)μmol/L,TBiL was(88.78±11.75)μmol/L,and TBA was(66.74±4.27)μmol/L,which were higher than those of the reference group[(71.57±5.85)U/L,(3.60±0.26)μmol/L,(11.24±3.03)μmol/L,and(7.01±0.04)μmol/L],and the differences were statistically significant(P<0.001).Conclusion Liver cirrhosis patients and healthy people have significant differences in liver related biochemical test indicators,which can diagnose the disease according to the data level,and provide sufficient data for later clinical treatment,which is conducive to the improvement of diagnostic accuracy.

关 键 词：肝硬化 生化检验 疾病诊断 临床治疗 准确度 肝胆功能 

分 类 号：R575[医药卫生—消化系统]